

ACTA MEDICINAE Speciál 2014 Kompletní literatura

Kazuistiky v onkologii a hematoonkologii

2 Léčba průlomové bolesti intranazálním fentanylem

MUDr. Radovan Hříb | MUDr. Marek Hák, Ph.D.

Centrum pro léčbu bolesti, Anesteziologicko-resuscitační klinika FN u svaté Anny v Brně

2 Axitinib v léčbě karcinomu ledviny

MUDr. Hana Študentová Onkologická klinika FN Olomouc

2 Pacientka s nádorovou průlomovou bolestí

MUDr. Jan Lejčko Centrum léčby bolesti, ARK, FN Plzeň

2 Mikrokalciifikace

MUDr. Monika Grilli Wagnerová Radiologická klinika FN KV Praha

2 Nilotinib v první linii léčby chronické myeloidní leukemie

MUDr. Hana Klamová, CSc. Ústav hematologie a krevní transfuze, Praha

2 Idiopatická trombóza

doc. MUDr. Petr Dulíček, Ph.D. | MUDr. Eva Ivanová | Mgr. Petr Sadílek

IV. interní hematologická klinika LF a FN v Hradci Králové, UK Praha

3 Pacient s chronickou myeloproliferací typu esenciální trombocytémie a s trombotickými komplikacemi

MUDr. Libor Červínek Interní hematologická a onkologická klinika LF MU a FN Brno

3 Elektrochemie jako nástroj pro studium antioxidační kapacity

Ondřej Zítka | Vojtěch Adam | René Kizek | Jaromír Hubálek Ústav chemie a biochemie, Agronomická fakulta, Mendelova univerzita v Brně, Ústav mikroelektroniky, Fakulta elektrotechniky a komunikačních technologií, VUT v Brně, Středoevropský technologický institut, VUT v Brně

Léčba průlomové bolesti intranazálním fentanylem

MUDr. Radovan Hříb | MUDr. Marek Hakl, Ph.D.

Centrum pro léčbu bolesti, Anesteziologicko-resuscitační klinika FN u svaté Anny v Brně

- 1 Portenoy, R. K. – Hagen, N. A.: Breakthrough pain: definition, prevalence and characteristics. *Pain*, 1990, 41 (3), s. 273–281.
- 2 Portenoy, R. K., et al.: Breakthrough pain: characteristics and impact in patients with cancer pain. *Pain*, 1999, 81 (1–2), s. 129–134.
- 3 Bennett, D., et al.: Consensus panel recommendations for the assessment and management of breakthrough pain. Part 2: management. *P&T*, 2005, 30, s. 354–361.
- 4 Smiths, H.: A Comprehensive review of rapid-onset opioids for breakthrough pain. *CNS Drugs*, 2012, 26 (6), s. 509–535.
- 5 SPC přípravku Instanyl.

Axitinib v léčbě karcinomu ledviny

MUDr. Hana Študentová Onkologická klinika FN Olomouc

- 1 Rini, B. I. – Escudier, B. – Tomczak, P., et al.: Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. *Lancet*, 2011, 378 (9807), s. 1931–1939.
- 2 Rini, B. I. – Melichar, B. – Takeshi, U., et al.: Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial. *Lancet Oncol*, 2013, 14, s. 1233–1242.

Pacientka s nádorovou průlomovou bolestí

MUDr. Jan Lejško Centrum léčby bolesti, ARK, FN Plzeň

- 1 WHO: Cancer pain relief: report of a WHO expert committee. 2nd edition, WHO 1996.
- 2 Rokyta, R. – Kršiak, M. – Kozák, J.: *Bolest*. Tígs, Praha, 2012.
- 3 Kolektiv autorů: Metodické pokyny pro farmakoterapii bolesti. *Bolest*, 2009, dopl. 2.
- 4 Počtenou, R. K. – Tailor, D. – Mesina, J., et al.: A randomised, placebo-controlled study of fentanyl buccal tablet for breakthrough in opioid-treated patients with cancer. *Clin J Pain*, 2006, 22 (9), s. 805–811.
- 5 Slatin, N. E. – Xie, F. – Mesina, J., et al.: Fentanyl buccal tablet for relief of breakthrough pain in opioid-tolerant patients with cancer-related pain. *J Support Oncol*, 2007, s. 327–334.
- 6 Einstein's – Messina, J. – Xie, et al.: Long-term safety profile of fentanyl buccal tablet for the treatment of breakthrough pain in opioid-tolerant patients with cancer. *Cancer*, 2009, s. 2571–2579.

Mikrokalcifikace

MUDr. Monika Grilli Wagnerová Radiologická klinika FN KV Praha

- 1 Baker, R. – Rogers, K. D. – Shepherd, N. – Stone, N.: New relationships between breast microcalcifications and cancer. *British Journal of Cancer*, 2010, doi: 10.1038/sj.bjc.6605873.
- 2 Depozita vápníku by mohla pomoci při diagnostice rakoviny prsu. Dostupné z: <http://www.mamo.cz/index.php?pg=pro-lekare&aid=347>, vyhledáno 28. 1. 2014.
- 3 Brejchová, Z., et al.: Mikrokalcifikace jako prvotní příznak maligní léze v prsu. 2004, dostupné z: <http://www.linkos.cz/po-kongresu/databaze-tuzemskych-onkologickych-konferencnich-abstrakt/abstrakta/cislo/668/>, vyhledáno 28. 1. 2014.
- 4 Schneiderová, M.: *Kontroverze v indikacích magnetické rezonance prsu v detekci karcinomu prsu*. Dostupné z: <http://www.linkos.cz/po-kongresu/databaze-tuzemskych-onkologickych-konferencnich-abstrakt/abstrakta/cislo/4454/>, vyhledáno 28. 1. 2014.
- 5 Chmelová, J.: *Metody vyšetření prsu*. Dostupné z: <http://www.silesia-medical.cz/komplexni-sluzby/centrum-pro-nemoci-prsu/centrum-pro-nemoci-prsu.html>, vyhledáno 28. 1. 2014.
- 6 Strnád, P.: *Nemoci prsu*. Dostupné z: <http://www.senologie.cz/cinnost/nemoci-prsu.php>, vyhledáno 28. 1. 2014.

Nilotinib v první linii léčby chronické myeloidní leukemie

MUDr. Hana Klamová, CSc. Ústav hematologie a krevní transfuze, Praha

- 1 Indrák, K. – Faber, E.: Nilotinib. *Farmakoterapie*, 2008, 4, s. 157–163.
- 2 Hehlmann, R. – Hochhaus, A. – Baccarani, M.: Chronic myeloid leukaemia. *Lancet*, 2007, 370, s. 342–350.
- 3 Faderl, S. – Talpaz, M. – Estrov, Z., et al.: Chronic myelogenous leukemia: biology and therapy. *Ann Intern Med*, 1999, 131, s. 207–219.
- 4 Kantarjian, H. – Gilda, F. – Wunderle, L., et al.: Nilotinib in imatinib resistant CML and Philadelphia chromosome-positive ALL. *N Engl J Med*, 2006, 354, s. 2542–2551.
- 5 Saglio, G. – Kin, D. W. – Issaragrisil, S., et al.: Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. *N Engl J Med*, 2010, 362, s. 2251–2259.
- 6 Saglio, G. – LeCoutre, P. – Pasquini, R., et al.: Nilotinib versus imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 36-month follow-up. *Blood (ASH Annual Meeting Abstracts)*, 2011, 118, abstrakt 452.
- 7 Cortes, J. E. – Jones, D. – O'Brien, S., et al.: Nilotinib as front-line treatment patients with chronic myeloid leukemia in early chronic phase. *J Clin Incol*, 2010, 28, s. 392–397.
- 8 Saglio, G., et al.: Update of the ENESTcmr Trial: Switching to nilotinib after residual disease on long-term imatinib continues to lead to deeper, prolonged molecular responses. *Blood*, 2013, 122, abstrakt 92.

Idiopatická trombóza

doc. MUDr. Petr Dulíček, Ph.D. | MUDr. Eva Ivanová | Mgr. Petr Sadílek

IV. interní hematologická klinika LF a FN v Hradci Králové, UK Praha

- 1 Elliot, M. A. – Tefferi, A.: Thrombosis and haemorrhage in polycythemia vera and essential thrombocythemia. *Br J Haematol*, 2005, 128, s. 275–290.
- 2 Jensen, M. K. – de Nully Brown, P. – Nielsen, O. J., et al.: Incidence, clinical features and outcome of essential thrombocythemia in a well defined geographical area. *European Journal of Hematology*, 2000, 65, s. 132–139.
- 3 Barbui, T. – Finazzi, G.: Indications for cytoreductive therapy in polycythemia vera and essential thrombocythemia. *Hematology*, 2003, 95, s. 202–209.
- 4 Regev, A. – Stark, P. – Blickstein, D., et al.: Thrombotic complications in Essential thrombocythemia with relatively low platelet counts. *Am J of Haematol*, 1997, 56, s. 168–172.

Pacient s chronickou myeloproliferací typu esenciální trombocytémie a s trombotickými komplikacemi

MUDr. Libor Červinek Interní hematologická a onkologická klinika LF MU a FN Brno

1 Klampfl, T. – Gisslinger, H. – Cazzola, M. – Kralovic, R.: Somatic mutation of calreticulin in myeloproliferative neoplasm. *N. Eng J Med*, 2013, 369, s. 2379–2390.

Elektrochemie jako nástroj pro studium antioxidační kapacity

Ondřej Zítka | Vojtěch Adam | René Kizek | Jaromír Hubálek Ústav chemie a biochemie, Agronomická fakulta, Mendelova univerzita v Brně, Ústav mikroelektroniky, Fakulta elektrotechniky a komunikačních technologií, VUT v Brně, Středoevropský technologický institut, VUT v Brně

- 1 Antolovich, M., et al.: Methods for testing antioxidant activity. *Analyt*, 2002, 127, s. 183–198.
- 2 RiceEvans, C. A. – Miller, N. J. – Paganga, G.: Structure-antioxidant activity relationships of flavonoids and phenolic acids. *Free Radic Biol Med*, 1996, 20, s. 933–956.
- 3 Sochor, J., et al.: Fully automated spectrometric protocols for determination of antioxidant activity: advantages and disadvantages. *Molecules*, 2010, 15, s. 8618–8640.
- 4 Sochor, J., et al.: An assay for spectrometric determination of antioxidant activity of a biological extract. *Lis Cukrov Repar*, 2010, 126, s. 416–417.
- 5 Riceevans, C. A., et al.: The relative antioxidant activities of plant-derived polyphenolic flavonoids. *Free Radic Res*, 1995, 22, s. 375–383.
- 6 Zloczower, M., et al.: Relationship of flow rate, uric acid, peroxidase, and superoxide dismutase activity levels with complications in diabetic patients: Can saliva be used to diagnose diabetes? *Antioxid Redox Signal*, 2007, 9, s. 765–773.
- 7 Rop, O., et al.: Antioxidant capacity, scavenging radical activity and selected chemical composition of native apple cultivars from central Europe. *J Food Qual*, 2011, 34, s. 187–194.
- 8 Rop, O., et al.: Phenolic content, antioxidant capacity, radical oxygen species scavenging and lipid peroxidation inhibiting activities of extracts of five black chokeberry (*Aronia melanocarpa* (Michx.) Elliot) cultivars. *J Med Plants Res*, 2010, 4, s. 2431–2437.
- 9 Rop, O., et al.: Antioxidant and radical oxygen species scavenging activities of 12 cultivars of blue honeysuckle fruit. *Hortic Sci*, 2011, 38 (2), s. 63–70.
- 10 Rop, O., et al.: Effect of five different stages of ripening on chemical compounds in medlar (*Mespilus germanica* L.). *Molecules*, 2011, 16, s. 74–91.
- 11 Sochor, J., et al.: Evaluation of output signals from CoulArray detector for determination of antioxidant capacity of apricots samples. In: Jan, J., et al. (eds.): *Analysis of biomedical signals and images*, 2010, Univ Technology Vut Press, Brno, s. 209–214.
- 12 Sochor, J., et al.: A study of availability of heavy metal ions by using various extraction procedures and electrochemical detection. *Lis Cukrov Repar*, 2010, 126, s. 414–415.
- 13 Sochor, J., et al.: Mathematical evaluation of the amino acid and polyphenol content and antioxidant activities of fruits from different apricot cultivars. *Molecules*, 2011, 16, s. 7428–7457.
- 14 Sochor, J., et al.: Content of phenolic compounds and antioxidant capacity in fruits of apricot genotypes. *Molecules*, 2010, 15, s. 6285–6305.
- 15 Pohanka, M., et al.: Automated assay of the potency of natural antioxidants using pipetting robot and spectrophotometry. *J Appl Biomed*, 2012, 10, s. 155–167.
- 16 Prieto-Simon, B., et al.: Electrochemical biosensors as a tool for antioxidant capacity assessment. *Sens Actuator B-Chem*, 2008, 129, s. 459–466.
- 17 Campanella, L. – Martini, E. – Tomassetti, M.: Antioxidant capacity of the algae using a biosensor method. *Talanta*, 2005, 66, s. 902–911.
- 18 Barroso, M. F. – Delerue-Matos, C. – Oliveira, M.: Electrochemical evaluation of total antioxidant capacity of beverages using a purine-biosensor. *Food Chem*, 2012, 132, s. 1055–1062.
- 19 Andlauer, W. – Heritier, J.: Rapid electrochemical screening of antioxidant capacity (RESAC) of selected tea samples. *Food Chem*, 2011, 125, s. 1517–1520.
- 20 Ying, W., et al.: An electrochemical method for sensitive determination of antioxidant capacity. *Electroanalysis*, 2009, 21, s. 1395–1400.
- 21 Kremplova, M., et al.: Automated Electrochemical Detection of Iron Ions in Erythrocytes from MeLiM Minipigs Suffering from Melanoma. *Int. J. Electrochem. Sci*, 2012, 7, s. 5893–5909.
- 22 Barros, L., et al.: Antioxidant activity of *Agaricus* sp mushrooms by chemical, biochemical and electrochemical assays. *Food Chem*, 2008, 111, s. 61–66.
- 23 Kohen, R. – Fanberstein, D. – Tirosh, O.: Reducing equivalents in the aging process. *Arch Gerontol Geriatr*, 1997, 24, s. 103–123.
- 24 Kostecki, R. – Song, X. Y. – Kinoshita, K.: Carbon microstructures for electrochemical studies. *Electrochemistry of Carbon Materials*, ed. McDermott, M. T. – Belanger, D. – Zaghib, K., 2004, 2000, Pennington: Electrochemical Society Inc., s. 19–25.
- 25 Martinez, S., et al.: Cyclic voltammetry study of plasma antioxidant capacity—Comparison with the DPPH and TAS spectrophotometric methods. *J Electroanal Chem*, 2006, 588, s. 68–73.
- 26 Martins, R. C., et al.: Oxidation management of white wines using cyclic voltammetry and multivariate process monitoring. *J Agric Food Chem*, 2008, 56, s. 12092–12098.
- 27 McMillan, D. C., et al.: Role of oxidant stress in lawsone-induced hemolytic anemia. *Toxicol Sci*, 2004, 82, s. 647–655.
- 28 Mittal, A., et al.: Redox status of acute pancreatitis as measured by cyclic voltammetry: Initial rodent studies to assess disease severity. *Crit Care Med*, 2008, 36, s. 866–872.
- 29 Arribas, A. S. – Martinez-Fernandez, M. – Chicharro, M.: The role of electroanalytical techniques in analysis of polyphenols in wine. *Trac-Trends Anal Chem*, 2012, 34, s. 78–96.
- 30 Jelen, F., et al.: Voltammetric study of adenine complex with copper on mercury electrode. *Electroanalysis*, 2009, 21, s. 439–444.
- 31 Adam, V., et al.: Vertebrate metallothioneins as target molecules for analytical techniques. *Trac-Trends Anal Chem*, 2010, 29, s. 409–418.
- 32 Bard, A. J. – Faulkner, L. R.: *Electrochemical methods—Fundamentals and applications*. Vol. Second edition. 2001, New York, Wiley-VCH.
- 33 Wang, J.: *Analytical electrochemistry*. Vol. Second edition. 2000, New York, Wiley-VCH.
- 34 Hynek, D., et al.: Study of interactions between cysteine and cadmium(II) ions using automatic pipetting system off-line coupled with electrochemical analyser dedicated United Nations Environment Program: Lead and cadmium initiatives. *Int J Electrochem Sci*, 2012, 7, s. 1802–1819.
- 35 Kilmartin, P. A. – Zou, H. L. – Waterhouse, A. L.: Correlation of wine phenolic composition versus cyclic voltammetry response. *Am J Enol Vitic*, 2002, 53, s. 294–302.
- 36 Mittal, A., et al.: The redox status of experimental hemorrhagic shock as measured by cyclic voltammetry. *Shock*, 2010, 33, s. 460–466.
- 37 Abdel-Hamid, R. – Newair, E. F.: Electrochemical behavior of antioxidants: I. Mechanistic study on electrochemical oxidation of gallic acid in aqueous solutions at glassy-carbon electrode. *J Electroanal Chem*, 2011, 657, s. 107–112.
- 38 Apetrei, C., et al.: Carbon paste electrodes made from different carbonaceous materials: Application in the study of antioxidants. *Sensors*, 2011, 11, s. 1328–1344.
- 39 Medvidovic-Kosanovic, M., et al.: Electrochemical and antioxidant properties of rutin. *Collect Czech Chem Commun*, 2010, 75, s. 547–561.
- 40 Reis, N. S., et al.: Electrochemical methods used for evaluation of antioxidant activity of natural products. *Lat Am J Pharm*, 2009, 28, s. 949–953.
- 41 Diopon, V., et al.: Electrochemical and spectrometric study of antioxidant activity of pomiferin, isopomiferin, osajin and catalposide. *J Pharm Biomed Anal*, 2008, 48, s. 127–133.
- 42 Papanikos, A., et al.: Cyclic voltammetry as an indicator of antioxidant activity. *Aust J Chem*, 2002, 55, s. 205–212.
- 43 Ruffien-Ciszak, A., et al.: Exploration of the global antioxidant capacity of the stratum corneum by cyclic voltammetry. *Journal of Pharmaceutical and Biomedical Analysis*, 2006, 40, s. 162–167.
- 44 Chevion, S. – Chevion, M.: Antioxidant status and human health—Use of cyclic voltammetry for the evaluation of the antioxidant capacity of plasma and of edible plants, in reactive oxygen species: From radiation to molecular biology: A Festschrift in Honor of Daniel L. Gilbert, C. C. Chiueh, Editor. 2000, New York Acad Sciences: New York, s. 308–325.
- 45 Chevion, S., et al.: The antioxidant properties of thioctic acid: Characterization by cyclic voltammetry. *Biochemistry and Molecular Biology International*, 1997, 41, s. 317–327.
- 46 Koren, E., et al.: Total oxidant-scavenging capacities of plasma from glycogen storage disease type Ia patients as measured by cyclic voltammetry, FRAP and luminescence techniques. *Journal of Inherited Metabolic Disease*, 2009, 32, s. 651–659.
- 47 Barroso, M. F., et al.: Electrocatalytic evaluation of DNA damage by superoxide radical for antioxidant capacity assessment. *Journal of Electroanalytical Chemistry*, 2011, 659, s. 43–49.
- 48 Fridovich, I.: Superoxide radical and superoxide dismutases. *Annual Review of Biochemistry*, 1995, 64, s. 97–112.
- 49 Arimura, Y., et al.: Mitochondrial superoxide production contributes to vancomycin-induced renal tubular cell apoptosis. *Free Radical Biology and Medicine*, 2012, 52, s. 1865–1873.
- 50 Mitozo, P. A., et al.: A study of the relative importance of the peroxiredoxin-, catalase-, and glutathione-dependent systems in neural peroxide metabolism. *Free Radical Biology and Medicine*, 2011, 51, s. 69–77.
- 51 Graca-Souza, A. V., et al.: Adaptations against heme toxicity in blood-feeding arthropods. *Insect Biochemistry and Molecular Biology*, 2006, 36, s. 322–335.
- 52 Pohanka, M., et al.: Ferric reducing antioxidant power and square wave voltammetry for assay of low molecular weight antioxidants in blood plasma: Performance and comparison of methods. *Sensors*, 2009, 9, s. 9094–9103.
- 53 Qian, P., et al.: Evaluation of DNA damage and antioxidant capacity of sericin by a DNA electrochemical biosensor based on dendrimer-encapsulated Au-Pd/chitosan composite. *Microchimica Acta*, 2010, 168, s. 347–354.
- 54 Ziyatdinova, G. – Labuda, J.: Complex electrochemical and impedimetric evaluation of DNA damage by using DNA biosensor based on a carbon screen-printed electrode. *Analytical Methods*, 2011, 3, s. 2777–2782.
- 55 Cahova-Kucharikova, K., et al.: Use of DNA repair enzymes in electrochemical detection of damage to DNA bases in vitro and in cells. *Analytical Chemistry*, 2005, 77, s. 2920–2927.
- 56 Firuzi, O., et al.: Evaluation of the antioxidant activity of flavonoids by "ferric reducing antioxidant power" assay and cyclic voltammetry. *Biochimica Et Biophysica Acta-General Subjects*, 2005, 1721, s. 174–184.